NCT06062576

Brief Summary

Yunnan Baiyao has been treating all kinds of wounds for 120 years, but the evidence of Evidence-based medicine that is truly convincing is insufficient, making its best application method unclear. This study explored the possible indications and use methods of Yunnan Baiyao in different stages of Diabetic foot, and obtained Evidence-based medicine evidence of clinical efficacy. Obtain the discarded tissues of Diabetic foot patients in the treatment and control groups of Yunnan Baiyao after wound debridement, conduct Transcriptome (BulkRNA seq) analysis and detection on the wound tissues, and analyze the related signal pathways and functional genes with significant differences, to help clarify the possible treatment targets of Yunnan Baiyao.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Dec 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 2, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

June 25, 2024

Status Verified

June 1, 2024

Enrollment Period

1.1 years

First QC Date

September 25, 2023

Last Update Submit

June 21, 2024

Conditions

Keywords

Diabetic FootTherapeutics

Outcome Measures

Primary Outcomes (1)

  • 2-week reduction rate of wound area

    Difference in wound area before and after treatment

    2 weeks

Study Arms (6)

control group 1

NO INTERVENTION

The optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks

powder group 1

EXPERIMENTAL

On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks

Drug: Yunnan Baiyao

ointment group 1

EXPERIMENTAL

On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks

Drug: Yunnan Baiyao

control group 2

NO INTERVENTION

The optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks

powder group 2

EXPERIMENTAL

On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks

Drug: Yunnan Baiyao

ointment group 2

EXPERIMENTAL

On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks

Drug: Yunnan Baiyao

Interventions

On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks

ointment group 1ointment group 2powder group 1powder group 2

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The age of the subjects is 18-80 years old;
  • Diagnose diabetes according to WHO standards;
  • Diagnosis of Diabetic foot;
  • Confirmed as one of the stages of infection progression and granulation growth;
  • Voluntarily participate in this study and sign an informed consent form.

You may not qualify if:

  • Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;
  • Blood glucose is out of control, Glucose test#Fasting blood sugar\>15mmol /L, Glycated hemoglobin\>12%;
  • There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented;
  • Serum albumin\<20g/L; Hemoglobin\<60g/L; Platelets\<50 × 109/L;
  • Late stage subjects with malignant tumors;
  • Active period of autoimmune diseases;
  • Have a history of allergy to Yunnan Baiyao;
  • The subject is unable to cooperate or has mental disorders;
  • According to the judgment of the researcher, the subject has a clear reason that cannot be removed and affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University 3rd Hospital

Beijing, Beijing Municipality, 100191, China

RECRUITING

MeSH Terms

Conditions

Diabetic Foot

Interventions

yunnan baiyao

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 25, 2023

First Posted

October 2, 2023

Study Start

December 1, 2023

Primary Completion

December 31, 2024

Study Completion

June 30, 2025

Last Updated

June 25, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations